Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Spectral Medical Inc T.EDT

Alternate Symbol(s):  EDTXF

Spectral Medical Inc. is a Canada-based late-stage theragnostic company advancing therapeutic options for sepsis and septic shock. The Company develops and commercializes a treatment for septic shock utilizing its Endotoxin Activity Assay (EAA) diagnostic and the Toraymyxin therapeutic (PMX). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company’s EAA. PMX is approved for therapeutic use in Japan and Europe and has been used safely and effectively on more than 340,000 patients to date. It has pioneered the development of biochemical markers for the clinical syndrome known as septic shock. It is continuing its legacy business of manufacturing and selling certain proprietary reagents. It develops, produces and markets recombinant proteins, antibodies and calibrators. These materials are sold for use in research and development, as well as in products manufactured by other diagnostic companies.


TSX:EDT - Post by User

Post by mercedesmanon Apr 30, 2021 9:47am
211 Views
Post# 33100319

More proof on extended duration of PMX-DHP !

More proof on extended duration of PMX-DHP !
https://read.qxmd.com/read/33910191/impact-of-extended-duration-of-polymyxin-b-immobilized-fiber-column-direct-hemoperfusion-on-hemodynamics-vasoactive-substance-requirement-and-pulmonary-oxygenation-in-patients-with-sepsis-an-observational-study


"DISCUSSION/CONCLUSIONS: Longer duration of PMX-DHP was associated with the improved MAP and decreased volume of vasoactive-inotropic agents compared with the conventional duration. Eight and longer hours duration of PMX-DHP was associated with the improvement in the pulmonary oxygenation. Further studies are needed to confirm the efficacy of longer duration of PMX-DHP in patients with septic shock."

Three points:

Who knew that by removing more endotoxins (perhaps until the infection sourse has been adequantely controlled) would improve outcomes?

Wonder how the FDA will deal with this complelling new real world evidence as they finalize their reiew of Tigris results?

Would using more filters or higher capacity filters increase the long term revenues of Spectral assuming FDA approva?  Hmmmm?!

MM


 

<< Previous
Bullboard Posts
Next >>